Topics

Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease

06:18 EDT 10 Sep 2019 | Pharmaceutical Business Review

The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated

The post Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease appeared first on Pharmaceutical Business review.

Original Article: Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease

NEXT ARTICLE

More From BioPortfolio on "Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease"

Quick Search